retatrutide approval status 2025 fda PolitiFact Retatrutide FDA Approval 2025–2026: Phase

Tirzepatide users (Mounjaro, Zepbound): The window is slightly shorter four days (96 hours)

This dramatic increase in weight reduction capabilities naturally leads to speculation around additional health benefits for multiple conditions, including diabetes, cardiovascular, sleep apnea, and others for which medical devices and procedures are often part of management and treatment regimens

Projected revenue for each product from 2025 through 2030, based on consensus estimates from Wall Street analysts, are used to calculate the forecasted cumulative revenue to the end of the decade

Seek immediate help if you are experiencing a medical emergency